1. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189– 199.
2. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‑ Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835– 3849.
3. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079– 2088. Erratum Blood 1998; 91: 1100.
4. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454– 2465.
5. Schanz J, Tüchler H, Solé F et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820– 829.
6. Armand P, Kim HT, Aleya EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586– 4588.
7. Leitch HA, Wong D, Leger C et al. Improved leukemia‑free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. Blood 2007; 110: abstract 1469.
8. Rose C, Brechignac S, Fenaux P et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 2007; 110: Abstract 249.
9. Park S, Grabar S, Kelaidi C et al. GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G‑CSF: the GFM experience. Blood 2008; 111: 574– 582.
10. Hellström‑ Lindberg E, Gulbrandsen N, Lindberg G et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‑ stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037– 1046.
11. Thompson JA, Gilliland DG, Prchal JT et al. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony‑ stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/ EPO MDS Study Group. Blood 2000; 95: 1175– 1179.
12. Jonasova A, Neuwirtova R, Cermak J et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304– 309.
13. Killick SB, Mufti G, Cavenagh JD et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‑ risk’ myelodysplasia. Br J Haematol 2003; 120: 679– 684.
14. Shimamoto T, Tohyama K, Okamoto T et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 2003; 27: 783– 788.
15. Molldrem JJ, Jiang YZ, Barrett AJ et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‑ mediated inhibition of CFU‑ GM and alterations in T‑ cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314– 1322.
16. Sloand EM, Mainwaring L, Barrett AJ et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841– 851.
17. Barrett J, Sloand E, Young N. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment. Haematologica 2006; 91: 583– 584.
18. Lee SE, Kim YJ, Yahng SA et al. Survival benefits from reduced‑ intensity conditioning in allogeneic stem cell transplantation for young lower‑ risk MDS patients without significant comorbidities. Eur J Haematol 2011; 87: 510– 520.
19. Luger SM, Ringdén O, Zhang MJ et al. Similar outcomes using myeloablative vs reduced‑ intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203– 211.
20. Lee SE, Lim J, Yahng SA et al. Reduced‑ intensity conditioning regimen combined with low‑dose total body irradiation in the treatment of myelodysplastic syndrome. Acta Haematol 2011; 126: 21– 29.
21. Jabbour E, Mathisen MS, Garcia‑ Manero Get al. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case‑ control study. Am J Hematol 2013; 88: 198– 200.
22. Raza A, Meyer P, Dutt D et al. Thalidomide produces transfusion independence in long‑standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958– 965.
23. List A, Dewald G, Raza A et al. Myelodysplastic Syndrome‑ 003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456– 1465.
24. Fenaux P, Giagounidis A, Selleslag D et al. MDS‑ 004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion‑ dependent patients with Low‑ / Intermediate‑ 1- risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765– 3776.
25. Jädersten M, Saft L, Mufti GJ et al. TP53 mutations in low‑ risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971– 1979.
26. Raza A, Reeves JA, List AF et al. Phase 2 study of lenalidomide in transfusion‑ dependent, low‑ risk, and intermediate‑ 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86– 93.
27. Hofmann WK, Takeuchi S, Takeuchi N et al. Comparative analysis of hypermethylation of cell cycle control and DNA‑ mismatch repair genes in low‑ density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. Leuk Res 2006; 30: 1347– 1353.
28. Christiansen DH, Andersen MK, Pedersen‑ Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy‑related myelodysplasia and acute myeloid leukemia. Leukemia 2003; 17: 1813– 1819.
29. Curik N, Burda P, Vargova K et al. 5- azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 2012; 26: 1804– 1811.
30. Shin DY, Park YS, Yang K et al. Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int J Oncol 2012; 41: 910– 918.
31. Silverman LR, Demakos EP, Peterson BL et al.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429– 2440.
32. Fenaux P, Mufti GJ, Hellstrom‑ Lindberg E et al. International Vidaza High‑Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‑ risk myelodysplastic syndromes: a randomised, open‑ label, phase III study. Lancet Oncol 2009; 10: 223– 232.
33. Itzykson R, Thépot S, Quesnel B et al. Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher‑ risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403– 411.
34. Grövdal M, Khan R, Aggerholm A et al. Maintenance treatment with azacitidine for patients with high‑risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after intensive chemotherapy. Br J Haematol 2010; 150: 293– 302.
35. Damaj G, Duhamel A, Robin M et al. Impact of azacitidine before allogeneic stem‑ cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie‑ Cellulaire and the Groupe‑ Francophone des Myelodysplasies. J Clin Oncol 2012; 30: 4533– 4540.
36. Silverman LR, Fenaux P, Mufti GJ et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‑ risk myelodysplastic syndromes. Cancer 2011; 117: 2697– 2702.